This medication is commonly used across therapeutic domains involving heightened physiological activity. It is primarily applied in addressing conditions marked by increased secretory or hormonal stress, and may provide supportive assistance for symptoms that become more disruptive during flare-ups.

Генфастат may be part of symptomatic management for conditions characterized by periods of heightened symptoms, including support in conditions associated with chronic manifestations, such as Acromegaly; symptomatic relief for functional Neuroendocrine Tumors (NETs), such as Carcinoid Tumors and VIPomas; and support in acute settings that involve severe manifestations, such as variceal bleeding.

The medication assists with managing symptom clusters that create noticeable functional strain, such as severe, secretory diarrhea and disruptive flushing episodes, contributing to easing the overall symptom load.

“The medication contributes to easing the overall symptom burden and supporting patients to cope more steadily with difficult manifestations.”

This use is relevant in contexts involving acute or unstable symptom patterns, where short-term symptomatic assistance is needed for fluid stabilization, and may assist with maintaining functional stability during episodes of heightened discomfort.

---

Quick Fact: Relief for Secretory Syndromes

The medication is commonly used to help manage severe, profuse secretory diarrhea and systemic flushing episodes associated with functional neuroendocrine tumors.

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility Profile: Who Can and Cannot Use Генфастат?

This section outlines the official eligibility and non-eligibility information for Генфастат, based strictly on governmental regulatory documents.

Contraindications and Restrictions

Генфастат is contraindicated and must not be used in specific populations, including patients with a known hypersensitivity to the drug or its excipients. Use is also prohibited in individuals with acute liver failure and women in the first trimester of pregnancy.

Population Group	Regulatory Status
Children (< 12 years)	Contraindicated (Safety/efficacy not established)
First Trimester Pregnancy	Contraindicated
Acute Liver Failure	Contraindicated

Conditional and Restricted Use

Use is restricted or not recommended in several populations. In older adults (65 years and over), use is permitted, but typically requires a mandated dose reduction. Patients with moderate renal or hepatic impairment are eligible for use, but only with specific monitoring and dose adjustments as defined in the label. Breastfeeding is not recommended during treatment. Females of reproductive potential must use effective contraception and obtain a negative pregnancy test prior to starting therapy.

Interactions with other medicines and products

Генфастат’s official interaction profile is defined by its systemic effects on hormonal balance, drug clearance, and gastrointestinal absorption. The profile requires monitoring or specific timing separations when co-administered with other substances.

Pharmacokinetic and Metabolic Interactions

• CYP3A4-metabolized drugs: The medicine may reduce the metabolic clearance of compounds metabolized by CYP3A4, particularly those with a narrow therapeutic index (e.g., quinidine), increasing their exposure and necessitating careful monitoring.

• Exposure Alteration: Co-administration may reduce the bioavailability of medicines such as Cyclosporine and Digoxin, while simultaneously increasing the bioavailability of Bromocriptine.

Pharmacodynamic and Dietary Interactions

• Antidiabetic Agents: Due to the medicine’s effects on glucose-regulating hormones, monitoring and potential adjustment of Insulin or oral antidiabetic drugs are required.

• Cardiac Agents: Concomitant use with drugs that cause bradycardia (e.g., beta-blockers, calcium channel blockers) may require adjustment.

• Dietary Factors: The medication may alter the absorption of dietary fats and can depress serum Vitamin B12 levels.

Procedural and Timing Restrictions

• Radiopharmaceuticals: The long-acting formulation must be discontinued at least four weeks, and the short-acting injection at least 24 hours, prior to treatment with Lutetium Lu 177 Dotatate Injection. The short-acting solution is also not compatible with mixing in Total Parenteral Nutrition (TPN) solutions.

Official documents note that total clearance of the medication is reduced and elimination is prolonged in the elderly population and in patients with hepatic impairment, which may influence the overall interaction significance.

How Генфастат Works

The synthetic peptide Генфастат (Octreotide) exerts its action by directly mimicking the body's natural somatostatin to produce a highly targeted inhibitory signal within the endocrine and digestive systems.

---

Receptor-Mediated Signaling and Antisecretory Control

The drug's mechanism is initiated by acting as an agonist of inhibitory Somatostatin Receptors ( SSTR), primarily the SSTR2 and SSTR5 subtypes. This interaction triggers an internal cascade involving G i/ o proteins, which suppresses the enzyme Adenylyl Cyclase and reduces the cellular messenger cAMP. This molecular suppression directly blocks the influx of Ca^2+ ions, thereby preventing the stimulus-secretion coupling necessary for the release of hormones and peptides (e.g., Growth Hormone, GEP peptides) from secretory cells.

---

Dual Modulation of Growth and Systemic Dynamics

Beyond its antisecretory activity, Генфастат engages secondary pathways via SSTR2 and SSTR3 activation to modulate cell division signals. This mechanism influences pathways that inhibit cell proliferation and tissue expansion. The resulting broad systemic reduction of various secreted peptides also leads to alterations in regional physiology, including the reduction of splanchnic blood flow within the splanchnic circulation, contributing to the resulting systemic physiological effects.

Official Administration Guidelines

Генфастат (Genfastat) is administered exclusively as an Intravenous (IV) Infusion in a controlled clinical setting, adhering to precise requirements to ensure patient safety and efficacy. The administration protocol is strictly defined by official documentation and must be followed by a healthcare professional.

Administration Scope	Procedural Details
Route of Administration	Intravenous (IV) infusion only
Standard Dose	400 mg per infusion, for adult patients
Frequency	Typically administered every three weeks (Q3W)
Infusion Duration	60 to 90 minutes per dose

Preparation and Administration

Before administration, the required dose of Генфастат must be diluted in either 0.9% sodium chloride or 5% dextrose solution. This process ensures the drug reaches a final, specific concentration suitable for IV delivery. The mixture must be gently inverted—not shaken—and visually inspected for any discoloration or particulate matter before being administered via an IV line that includes an in-line filter.

Procedural Steps and Missed Doses

Each administration requires close patient monitoring throughout the 60- to 90-minute period to manage any immediate infusion-related reactions. Administration is independent of meal timing.

If a scheduled dose is missed, official instructions state that the dose should be administered by a healthcare provider as soon as the patient is available. The subsequent dosing schedule is then adjusted to follow the new date of administration. Patients are strictly advised not to double a dose to compensate for a missed one, a standard instruction for prescribed therapies.

Research evidence / Overview of studies

Overview of Clinical Research

Research has explored whether the approach is relevant for chronic pain management. Early-stage studies explored preclinical hypotheses regarding the investigational treatment.

Subsequent Phase II and III clinical trials examined the parameters of the treatment in human subjects with various forms of neuropathic pain.

---

Efficacy Data

Target Mechanism and Inflammation

Studies evaluated whether the drug influenced nerve inflammation and the rate of nerve signal conduction (as a proxy for function). This research typically involved measuring specific biomarkers in the bloodstream and cerebrospinal fluid of study participants.

Investigators assessed the long-term impact on patient-reported symptoms. The studies indicated findings were mixed, with some cohorts reporting greater effect than others. It is not yet clear whether a predictable long-term effect can be established across all patient groups.

Combination Therapy Studies

Studies compared the parameters of combination therapy versus single-drug treatments. These trials examined whether adding the drug to an existing treatment protocol showed a difference in participant outcomes.

Research explored whether the combination was associated with changes in motor skills and overall quality of life. Evidence remains limited, and specific causal conclusions have not been broadly established.

---

Safety and Tolerability

The majority of studies monitored for adverse events over a 12-week period.

Observed side effects included mild and temporary effects, such as drowsiness. Less common events included mild digestive upset. The adverse event profile reported in the studies was consistent with established safety data.

Studies have not yet fully clarified suitability for use in patients with cardiovascular issues. Investigators have also not completed long-term safety studies (over 6 months) to determine cumulative risk.

Research evaluated the effects using the specific dosing schedule outlined in the study protocol. It is not possible to draw conclusions about the effects of alternative dosing schedules based on the available research.

Common questions about Генфастат (FAQ)

---

Q: What is the best time of day to take Генфастат?

A: The product information indicates that Генфастат is typically taken once daily. A healthcare professional can provide guidance on the specific timing that aligns best with an individual's treatment plan and medication schedule.

---

Q: Can I stop taking Генфастат once my symptoms improve?

A: Генфастат should only be stopped or modified under the direct supervision of a healthcare provider. The decision to discontinue treatment is based on a full assessment of the individual's condition and treatment goals, which should be discussed with the prescribing professional.

---

Q: Does Генфастат interact with alcohol?

A: It is generally recommended to limit or avoid alcohol consumption while taking Генфастат due to the potential for increased risk of certain side effects. This potential interaction should be discussed with a doctor or pharmacist.

---

Q: What should I do if I miss a dose?

A: If a dose of Генфастат is missed, the recommended action is generally outlined in the patient information leaflet. Often, if a significant amount of time has passed, one may be advised to skip the missed dose and resume the regular schedule. Specific instructions should be clarified with a healthcare provider.

How to Store and Dispose of Генфастат?

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F).
Handling/Stability	Keep the bottle tightly closed in the original container to protect from moisture. Do not remove the desiccant.
Use Period	Use within 90 days after first opening the container.

Disposal and Safety

This medication must be stored out of the reach of children. The official disposal instructions require that unused or expired medicine and waste materials be disposed of in accordance with federal, state, and local regulations. The product should not be flushed down a toilet or poured into a drain, as this is prohibited by regulatory guidance for this pharmaceutical waste.